RCT | Weekly Tirzepatide outperforms placebo in weight management for type 2 diabetes patients

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Tirzepatide triumphs in significant weight reduction for people with type 2 diabetes – News Medical